CONFLITO DE INTERESSES DECLARADO POR TODOS OS PROFISSIONAIS DE SAÚDE CITADOS ACIMA
De acordo com a resolução 1931/2009 do Conselho Federal de Medicina e com a RDC 96/2008 da ANVISA, declaro que recebi honorários da Gilead para esse evento.
Referências:
Bula Profissional Trodelvy.
Bardia A, Hurvitz SA, Tolaney SM, et al; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 Apr 22;384(16):1529-1541.
Carey LA, Loirat D, Punie K, et al. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. NPJ Breast Cancer. 2022 Jun 9;8(1):72.
Tolaney SM, Bardia A, Marmé F, et al. Final overall survival analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan in patients with hormone receptor positive/HER2-negative metastatic breast cancer [Oral Presentation 1003]. Presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2023; Chicago, IL
Os conteúdos acima são exclusivos aos profissionais de saúde habilitados a dispensar ou prescrever medicamentos.
